Mk2 interacting proteins
First Claim
Patent Images
1. An isolated, purified, or recombinant protein complex comprising:
- (i) an MK2 polypeptide; and
(ii) an MK2 interacting protein chosen from STS, HPH2 and Shc.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to uses of proteins that bind MK2 to modulate inflammation. More particularly, the invention relates to uses of proteins that bind MK2 for treating condition that are related to inflammation. The invention is useful for treating inflammatory conditions, particularly those in which a decrease in inflammation would be therapeutically beneficial.
17 Citations
61 Claims
-
1. An isolated, purified, or recombinant protein complex comprising:
-
(i) an MK2 polypeptide; and
(ii) an MK2 interacting protein chosen from STS, HPH2 and Shc. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 57, 58, 59, 60)
-
- 10. A host cell comprising a first nucleic acid and a second nucleic acid, wherein the first nucleic acid encodes a recombinant MK2 polypeptide and the second nucleic acid encodes an MK2 interacting protein chosen from STS, HPH2 and Shc.
-
12. An assay for determining whether a test compound inhibits or promotes formation of a protein complex comprising:
-
(a) forming a reaction mixture including an MK2 polypeptide, at least one MK2 interacting protein and the test compound; and
(b) detecting the presence of the protein complex between MK2 and the MK2 interacting protein;
wherein a difference in the amount of complex in the presence of the test compound, relative to the amount of complex in the absence of the test compound indicates that the test compound inhibits or promotes complex formation. - View Dependent Claims (13, 14)
-
-
15. A method for determining whether a test compound affects MK2 activity comprising:
-
(a) forming a protein complex comprising an MK2 polypeptide and an MK interacting protein;
(b) contacting the protein complex with the test compound, and (c) determining the effect of the test compound on one or more activities chosen from MK2 kinase activity, an amount of MK2 in the complex, production of TNF, and amount of phosphorylated form of a substrate of MK2.
-
-
16. A screening assay to identify compounds that inhibit or promote formation of a protein complex, comprising
(i) providing a two-hybrid assay system including a first fusion protein comprising an MK2 polypeptide, and a second fusion protein comprising a polypeptide chosen from one or more of STS, HPH2 and Shc, under conditions wherein the two proteins interact in the two hybrid assay system; -
(ii) measuring a level of interaction between the fusion proteins in the presence and in the absence of a test compound; and
(iii) comparing the level of interaction of the fusion proteins, wherein a decrease in the level of interaction is indicative of a compound that inhibits the interaction between the MK2 polypeptide and a polypeptide chosen from one or more of STS, HPH2 and Shc.
-
- 17. An antibody that binds one or more proteins in a complex comprising an MK2 polypeptide and an MK2 interacting protein chosen from STS, HPH2 and Shc.
-
19. A method for modulating formation of a protein complex in a cell comprising at least a first protein and a second protein, wherein the first protein is an MK2 polypeptide and the second protein is chosen from one or more of STS, HPH2 and Shc, and wherein the method comprises administering to the cell a compound capable of modulating formation of the complex.
-
20. A method of producing a complex comprising:
transfecting a cell with one or more polynucleotides encoding an MK2 polypeptide and an MK2 interacting protein chosen from one or more of STS, HPH2 and Shc, whereby the polypeptides form a complex.
-
21. A drug screening method for identifying anti-inflammatory drugs comprising:
-
a) providing MK2 and at least one MK2-interacting protein;
b) allowing MK2 and the protein to interact to form a complex;
c) adding an effective amount of a potential drug to the complex; and
d) determining whether the potential drug inhibits complex formation. - View Dependent Claims (22, 23, 24, 25, 26, 27, 28, 29, 30, 31)
-
-
32. A method of modulating inflammation in a tissue comprising:
-
a) administering a nucleic acid to the tissue, wherein the nucleic acid encodes an MK2 interacting protein; and
b) allowing the nucleic acid to express the MK2 interacting protein, thereby to modulate inflammation in the tissue. - View Dependent Claims (33)
-
-
34. A method of treating or preventing inflammation in a tissue comprising administering to the tissue a therapeutically effective amount of at least one agent, wherein the agent either
a) blocks the interaction between MK2 and an MK2 interacting protein; - or
b) allows the interaction, but blocks MK2 activity. - View Dependent Claims (35, 36, 37, 38, 39, 40, 41, 61)
- or
-
42. A method of modulating inflammation in a tissue comprising:
-
a) contacting the tissue with at least one protein that binds MK2; and
b) allowing the protein to modulate inflammation in the tissue.
-
-
43. A method of treating a patient suffering from at least one inflammatory condition, comprising:
-
a) administering a therapeutically effective dose of at least one compound chosen from a compound that interacts with at least one of MK2 or an MK2 complex, wherein the compound is chosen from an antibody, a chemical agent, a small molecule, a protein and a peptide; and
b) allowing the compound to bind to at least one of MK2 or an MK2 complex and modulate inflammation. - View Dependent Claims (44, 45, 46)
-
-
47. A method of expressing a nucleic acid in a cell to inhibit inflammation, comprising
a) adding at least one nucleic acid encoding a compound chosen from a compound that interacts with at least one of MK2 or an MK2 complex, wherein the compound is chosen from an antibody, a chemical agent, a small molecule, a protein and a peptide; - and
b) allowing the cell to express the compound and inhibit inflammation. - View Dependent Claims (48)
- and
-
49. A method of detecting at least one of the absence, presence, and amount of MK2 in a sample, comprising
a) administering at least one compound that interacts with at least one of MK2 or an MK2 complex, wherein the compound is chosen from an antibody, a chemical agent, a small molecule, a protein and a peptide; - and
b) correlating the absence, presence, or amount of bound protein or compound with the absence, presence, or amount of MK2 in the sample. - View Dependent Claims (50)
- and
-
51. A kit, wherein the kit enables qualitative detection of MK2 comprising a compound that interacts with at least one of MK2 or an MK2 complex, wherein the compound is chosen from an antibody, a chemical agent, a small molecule, a protein and a peptide;
- and at least one other kit component chosen from;
a) at least one of buffer and solution;
b) at least one structural component. - View Dependent Claims (52, 53, 54)
- and at least one other kit component chosen from;
-
55. A pharmaceutical composition comprising:
-
a) at least one protein that binds MK2, and b) at least one pharmaceutically acceptable carrier. - View Dependent Claims (56)
-
Specification